MERCK & CO. INC. (NYSE:MRK) was identified as a Technical Breakout Setup Pattern by our stockscreener. Such a pattern occurs when we see a pause in a strong uptrend: after a strong rise the stock is consolidating a bit and at some point the trend may be continued. Whether this actually happens can not be predicted of course, but it may be a good idea to keep and eye on NYSE:MRK.
ChartMill assigns a proprietary Technical Rating to each stock. The score is computed daily by evaluating various technical indicators and properties. The score ranges from 0 to 10.
Taking everything into account, MRK scores 9 out of 10 in our technical rating. Both in the recent history as in the last year, MRK has proven to be a steady performer, scoring decent points in every aspect analyzed.
Besides the Technical Rating, ChartMill also assign a Setup Rating to every stock. This setup score also ranges from 0 to 10 and determines to which extend the stock is consolidating. This is achieved by evaluating multiple short term technical indicators. NYSE:MRK currently has a 8 as setup rating:
MRK has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. A pullback is taking place, which may present a nice opportunity for an entry. There is a support zone below the current price at 109.93, a Stop Loss order could be placed below this zone.
A breakout could materialize when the stock breaks out to new highs above the current consolidation zone. One could wait for this to happen and buy when this happens. A stop loss could be placed below the consolidation zone.
Of course, there are many ways to trade or not trade NYSE:MRK and this article should in no way be interpreted as trading advice. The article is purely based on an automated technical analysis and just points out the technical observations. Always make your own analysis and trade at your own responsibility.
More breakout setups can be found in our Breakout analyzer.
These healthcare titans are poised for a strong showing in 2023 and beyond.
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Merck recently completed its acquisition of a California-based biotech company.
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.
The US FDA has granted an additional indication for Merck's (MRK) Keytruda (pembrolizumab) as a adjuvant therapy for non-small cell lung cancer (NSCLC).
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.